Glossary of Key Terms References Hendershot CS, Bremmer MP, Paladino MB, et al
Notwithstanding these developments, only about 20% of patients with T1D achieve adequate glycemic control based on current targets ( Based on recent data from National Health and Nutrition Examination Survey (NHANES) 2021-2023 ( Glucagon-like peptide-1 receptor agonists (GLP-1RA) are effective to treat adult and pediatric populations with type 2 diabetes (T2D) and/or obesity, and they have an established safety profile
GLP-1 provides systemic metabolic benefits: Reduced Visceral Fat: GLP-1 preferentially mobilizes harmful visceral adiposity (fat around organs), which drives inflammation and cardiometabolic disease
Thus, are changes in the gut bacterium itself beneficial to the host
Getting your GLP-1 prescription is only the first stepdiscover why personalized support can make all the difference throughout your journey
Important limitation: the Lancet trial enrolled only patients who had both alcohol use disorder and obesity
